advertisement
Abstract #15284 Published in IGR 8-4
Changes in glaucoma treatment and achieved IOP after introduction of new glaucoma medication
van der Valk R; Schouten JS; Webers CA; Hendrikse F; Prins MHGraefe's Archive for Clinical and Experimental Ophthalmology 2006; 244: 1267-1272
PURPOSE: To describe changes in glaucoma treatment and achieved IOP (intraocular pressure) over the period 1995-2002, 4 years before and 4 years after new glaucoma drugs had become available (January 1999). METHODS: An observational study was conducted in primary open-angle glaucoma (suspect), and ocular hypertension patients (n = 1561) who had started medical treatment in 1995 or thereafter. The processes of starting, changing and intensifying medical treatment in general, and in patients with contraindications to beta-blockers before and after January 1999 were described. The change in mean IOP and the percentage of patients achieving an intraocular pressure below 18 or 22 mmHg were calculated. RESULTS: After January 1999, a shift from starting on betaxolol to hypotensive lipids took place. This shift was more pronounced in patients with respiratory comorbidity. The percentage of patients starting on timolol did not differ between both periods. After January 1999, therapy was changed more often in the first two visits compared with the period before January 1999 (38% versus 27%, P < 0.0001). In more recent years, a larger percentage of glaucoma patients were treated with two or more drugs (34% in 2002 versus 13% in 1995). Over the period 1995-2002, baseline IOP did not change (P = 0.85); for mean IOP at visit 4, a trend to lower IOPs was observed (P < 0.0001). More patients achieved an IOP level under 22 and 18 mmHg after January 1999 than before, 85% versus 77%, and 46% versus 33%, respectively (P < 0.0001). CONCLUSIONS: This study shows a change in process of glaucoma treatment and lower achieved IOP after new glaucoma drugs had become available.
Dr. R. Van der Valk, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands
Classification:
11.1 General management, indication (Part of: 11 Medical treatment)
11.4 Prostaglandins (Part of: 11 Medical treatment)
